The Evolving Needs of Therapeutic mRNA Developers
Given the strides medical researchers and therapeutic developers were making, the possibility of commercializing mRNA therapeutics began looking bright about ten to fifteen years ago. However, one of the most pressing issues restricting researchers’ efforts was the lack of a reliable high-purity mRNA supply. There weren’t players that could readily and reliably provide end-to-end mRNA…
Leveraging mRNA to Revolutionize Antibody Manufacturing
How an mRNA-encoded antibody platform could accelerate therapies to clinic Therapeutic antibody production is traditionally complex and costly, which drives up treatment prices. However, encoding antibodies with mRNA offers a potential solution to many of these challenges, making the process more cost-effective and faster to reach clinical use. Recent data showing preclinical feasibility suggests that…
The mRNA Monthly—November 2024 Newsletter
mRNA for Antibody Manufacturing In collaboration, Charles River Lab and Vernal Biosciences released this scientific poster. Since its release, new advancements have been made and new data is available to share. Join the webinar on December 12 to dive into this new data and hear from the researchers directly. GET REGISTERED Clinical Trial: mRNA COVID-19…
Harnessing mRNA Quality Insights: Essential Techniques For Rapid Drug Development
In this talk, we dive into the critical quality attributes (CQAs) of mRNA and lipid nanoparticles (LNPs) that directly impact drug efficacy and safety. You’ll gain insights into essential and cutting-edge analytical techniques and nanopore sequencing, mass spectrometry, and laser-induced fluorescence capillary gel electrophoresis. Mastering these methods and CQAs is vital for drug developers looking…
Vernal Appoints Jim Petrilla as CEO and Board Director
New Leadership Reflects Commitment to Advancing mRNA Technologies and Operational Excellence, Helping Drug Developers Deliver Innovative Therapies Faster. COLCHESTER, Vt., October 31, 2024 /BUSINESS WIRE/ — Vernal Biosciences Inc., a leader in mRNA and lipid nanoparticle (LNP) development, manufacturing, and analytics, today announces the appointment of Jim Petrilla as Chief Executive Officer (CEO) and Board…
The mRNA Monthly—October 2024 Newsletter
Nature Nanotechnology: Tissue-Specific mRNA Therapeutic Delivery Researchers have developed a combinatorial design of siloxane-incorporated LNPs to enhance tissue-specific mRNA therapeutic delivery. This article explains how this approach improves intracellular processing and stability of mRNA, showing promise for targeted treatments and efficient gene expression in various tissues. READ MORE Nobel Prize in Physiology or Medicine Victor…